GleamWall
中文EN

BFNH BIOFORCE NANOSCIENCES HOLDINGS, INC.

Laboratory Analytical Instruments · OTC · SEC CIK 1310488 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY75.0%
TTM EPS YoY80.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-44.3%
ROA-28.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio7.23x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.39x
Accruals ratio-17.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
SG&A expense$66,951$67,437
Pretax income-$489,951-$490,437
Net income-$1.29M-$490,437
EPS (basic)-0.04-0.02
EPS (diluted)-0.04-0.02
Weighted avg. shares (diluted)33.21M29.27M
Balance sheet
Cash & equivalents$786$862
Current assets$786$862
Total assets$786$862
Current liabilities$619,329$2.30M
Total liabilities$619,329$2.30M
Shareholders' equity-$618,543-$2.30M
Shares outstanding33.52M29.27M
Cash flow statement
Operating cash flow-$65,150-$61,250
Financing cash flow$65,074$61,474

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.